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Received 12 April 2010; received in revised form 5 September 2010; accepted 10 September 2010Abstract We studied the susceptibility of human embryonic stem cells and derived contractile embryoid bodies from WAO9,
HUES-5 and HUES-16 cell lines to Coxsackievirus B infection. After validating stem cell-like properties and cardiac phenotype,
Coxsackievirus B receptors CAR and DAF, as well as type I interferon receptors were detected in all cell lines and differentiation
stages studied. Real-time PCR analysis showed that CAR mRNA levels were 3.4-fold higher in undifferentiated cells, while DAF
transcript levels were 2.78-fold more abundant in differentiated cultures (Pb0.05). All cell lines were susceptible to
Coxsackievirus serotypes B1-5 infection as shown by RT-PCR detection of viral RNA, immunofluorescence detection of viral
protein and infectivity titration of cell culture supernatants resulting in cell death. Supernatants infectivity titers 24-48 h post-
infection ranged from 105-106 plaque forming units (PFU)/ml, the highest titers were detected in undifferentiated cells. Cell
viability detected by a colorimetric assay, showed inverse correlation with infectivity titers of cell culture supernatants.
Treatment with 100 U of interferon Iβ significantly reduced viral replication and associated cell death during a 24–48
h observation period, as detected by reduced infectivity titers in the supernatants and increased cell viability by a colorimetric
assay, respectively. We propose human embryonic stem cell and derived contractile embryoid bodies as a valid model to study
cardiac Coxsackievirus B infection.
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Human embryonic stem cells (hESC) are derived from the inner
cell mass of an early embryo and possess a unique develop-
mental potential. They are defined as pluripotent because of
their capacity to differentiate into all cell lineages present in
embryonic tissue. In addition, hESC can self-renew and be
cultured indefinitely in vitro. Because hESC have been shown
to undergo robust in vitro differentiation, these cells may be.
14 M.E. Scassa et al.considered a powerful tool to explore different events
affecting cardiac cells (Lev et al., 2005), including molecular
pathogenesis and drug and toxicology testing (Steel et al.,
2009; Reppel et al., 2007). The development of induced
pluripotent stemcells (iPS) expands these possibilities further,
since it is now possible to study cardiomyocytes derived from
reprogrammed somatic cells of patients with cardiac disease
(Yokoo et al., 2009; Zhang et al., 2009).
Coxsackieviruses B (CVB), which include 6 serotypes, are
human enteroviruses belonging to the Picornaviridae family
(Pallansch and Roos, 2001). Together with CVA9 and the
echoviruses (EV), CVB are currently classified as type B
Enteroviruses (Stanway et al., 2004), interacting with at least
two receptor proteins present on the cytoplasmic membrane.
All CVB, as well as some adenoviruses, recognize and enter the
cell through the coxsackievirus-adenovirus receptor (CAR),
which is a 46-kDa protein belonging to the immunoglobulin
supergene family (Bergelson et al., 1997). Although viral
uncoating is initiated only by CAR interactions (Milstone et al.,
2005), some CVB interact with an additional 70-kDa molecule
known as the decay-accelerating factor (DAF, also known as
CD55), which is a surface-expressed complement regulatoryFigure 1 Expression of stem cell and cardiac markers in hESC at diff
transcriptswas performed on the undifferentiatedHUES-5 cells. (II) The
and then fixed and stainedwith primary antibodies recognizing stem ce
with TRA-1-160, Oct-4, Nanog and SSEA-4. (III) Semiquantitative RT-P
stages of differentiation; β-actin was used as a loading control (I and
onset of differentiation. The figure shows representative images of
Nkx2.5 and cTnT. The nuclei were counterstained with DAPI. The scale
Antigen 1-60; Oct-4, Octamer 4; SSEA-4, Stage-Specific Embryonic An
Mesp1, mesoderm posterior factor 1; Isl-1, Islet-1; α-MHC, α-myosin hprotein (Shafren et al., 1995). With the exception of CVB6, all
CVB serotypes are expected to produce similar diseases
(Pallansch and Roos, 2001); nevertheless, most experimental
studies have been performed with CVB3 because some viral
variants may induce myocarditis in animal models (Tracy and
Gauntt, 2008). CVB1 was the predominant enterovirus circu-
lating in the US during 2007 (Anon, 2008), and viruses derived
from an infectious clone (Iizuka et al., 1991) have been used in
several studies (Rinehart et al., 1997; Zhong et al., 2008).
Although CVB are a frequent cause of subclinical infection,
they may also cause other diseases such as viral myocarditis
(Pallansch and Roos, 2001), symptoms of which may be seen
either shortly after acute infection potentially triggering
severe myocardial dysfunction, or during the chronic phase
of disease resulting in dilated cardiomyopathy (DCM) (Feldman
andMcNamara, 2000; Yajima and Knowlton, 2009). Serological
data initially suggested a link between viral myocarditis and
DCM but with the exception of some pediatric cases, it was
almost impossible to detect infectious virus in cardiac tissue
samples from necropsies or biopsies. More recently, with the
aid of molecular procedures, multiple studies have detected
viral RNA (Feldman and McNamara, 2000; Ellis and Di Salvo,erent stages of differentiation. (I) RT-PCR analysis of stem cell-like
HUES-5 hESCwere grown on aMatrigelTM coated surface for 3 days
ll markers. The figure shows representative images of hESC stained
CR of cardiac-like transcripts was performed for hESC at different
III). (IV) Immunofluorescence staining of hESC at 14 days after the
contractile EB stained with primary antibodies for GATA-4, ANP,
bars represent 100 μm. Abbreviations: TRA-1-60, Tumor Rejection
tigen; ANP, atrial natriuretic peptide; cTnT, cardiac troponin T;
eavy chain.
15Coxsakievirus B infection and respond to interferon Iβ treatment2007) or viral proteins (Li et al., 2000) in heart tissue samples
from patients with acute viral myocarditis or DCM. Currently,
CVB are accepted as one of the most frequent viruses involved
in heart infections (Feldman and McNamara, 2000). At the
present time, no specific treatment is recommended for viral
myocarditis (Feldman and McNamara, 2000), although type I
interferon (IFN-I) has been recently administered topatients in
the chronic phase of the infection (Kuhl et al., 2003), aswell as
in ex vivo (Kandolf et al., 1985) and in vivo models of viral
myocarditis (Deonarain et al., 2004). In all of these studies,
IFN-I administration has shown promising results.
In this study, we show that both hESC and hESC-derived
contractile embryoid bodies (hESC-EB) from three different
cell lines express both CAR and DAF receptor transcripts and
proteins, as well as the interferon-α/β receptor α chain 1
(IFNAR1) and IFNAR2 transcripts. We also found that all cells
were susceptible to infection by the CVB1-5 strains. In
addition, IFN-Iβ treatment reduced CVB-induced cell lysis
and replication. We propose that hESC and hESC-EB as valid
ex vivo models for the study different aspects of CVB
infection of the heart.Figure 2 Expression of keymolecules thatmediate viral infection
(I) Semiquantitative RT-PCR was performed on the HUES-5, WA09
and HUES-16 at 0 and 14 days of differentiation;β-actin was used as
a loading control. (II) Immunofluorescence staining of HUES-5,WA09
and HUES-16 at 0 and 14 days of differentiation. The figure shows
representative images of HUES-5 undifferentiated colonies (top
panel) and EB (bottom panel) stained for CAR and DAF. The nuclei
were counterstained with DAPI. The scale bars represent 100 μm.
(III) Real-time RT-PCR analysis of CAR and DAFmRNA levels in HUES-
5 in hESC and contractile areas of EB. The GAPDHmRNA expressionResults
Analysis of stem cell and cardiac marker expression
in hESC and hESC-EB
We first validated the pluripotent nature of the hESC lines
used in this study by RT-PCR and immunofluorescence (IF)
microscopy. As shown in Fig. 1-I, undifferentiated hESC
expressed transcripts associated with pluripotency such as
Oct-4, Nanog and c-Myc. These cells also exhibited robust
expression of stem cell associated markers TRA1-60, Oct-4,
Nanog and SSEA-4 (Fig. 1-II) , thus indicating that under these
experimental conditions, hESC lines had retained self
renewal properties without visible differentiation.
Next, differentiation of hESC was induced using an EB-based
approach. On day 8, (after 7 days in suspension followed by
1 day of outgrowth in gelatin-coated dishes) we observed
formation of contracting regions, increasing in number there-
after. The proportion of contractile EB differed among the hESC
lines (HUES-5: 17.7±3.2%; WA-09: 8.9±2.5% and HUES-16: 3±
0.5%), beating spontaneously at an average frequency of 29±7.3
beats/min. This rate increased 49±6.2% compared to the
baseline after incubation with 10 nM of norepinephrine (NE).
To confirm the EB had acquired a cardiac phenotype, RT-PCR
and IF analyses were performed. Mesoderm expression (meso-
derm posterior factor-1, Mesp1), cardiac mesoderm (GATA-4,
GATA-6, Nkx2.5, Islet-1) and cardiomyocyte associated genes
(atrial natriuretic peptide,ANP; cardiacTroponinT, cTnTandα-
myosin heavy chain, α-MHC) was assessed 7 and 14 days after
the onset of differentiation (Fig. 1-III and IV). These results
demonstrate that the hESC had effectively differentiated into
EB-containing cardiomyocytes in vitro.level was used to normalize the expression data. Each bar
represents the mean ± SEM of three independent experiments. A
paired Student's t test was used to compare undifferentiated and
differentiated samples (*Pb0.05). Abbreviations: CA, contractile
areas; CAR, coxsackievirus-adenovirus receptor; DAF, decay-accel-
erating factor; IFNAR1, human interferon-α/ß receptor α chain 1;
IFNAR2, human interferon-α/β receptor α chain 2.hESC and hESC-EB express CAR, DAF and
IFN-I receptors
Next, we evaluated the expression of CVB and IFN-I receptors
in both the hESC and hESC-EB. To avoid contamination of
16 M.E. Scassa et al.cultures by mouse embryonic fibroblasts (MEF), hESC were
grown in feeder cell-free conditions (Matrigel™ coated dishes
and conditioned medium) for at least four passages prior to
cell harvest or viral infection. RT-PCR studies for CVB and
IFN-I receptors showed that all hESC lines studied expressed
the aforementioned molecules during both the undifferen-
tiated and differentiated stages (Fig. 2-I). Because the HUES-
5 cell line had the highest proportion of beating EB it was
selected for used in the subsequent studies. The presence of
both viral receptors was further confirmed by IF studies
(Fig. 2-II). To analyze the expression levels of CAR and DAF,
real-time RT-PCR analysis was performed. The results show
that the transcript level of CAR was 3.40±0.31 fold higher in
undifferentiated cells, while the DAF mRNA level was 2.78
±0.28 fold higher in the differentiated cells (Fig. 2-III)
(Pb0.05).CVB replicates in several hESC lines and hESC-EB
To evaluate the susceptibility of hESC and hESC-EB to CVB
infection, the cells were infected with CVB serotypes 1-5. In
hESC, a cytopathic effect (cpe), characterized by ballooning,
detachment and cell death was observed 12 h post-infection
(pi) and reached 80% of the monolayer at 24 h pi (Fig. 3-I and
IV). In the hESC-EB, a similar result was observed (Fig. 3-II),
although it was delayed because contractile areas stop
beating 48 h pi, later followed by cell lysis (supplementary
data). A few fibroblast-like cells did not show any cpe and
remained viable. The viral infectivity titration of super-
natants ranged between 105 to 106 PFU/ml. Higher titers
were detected in undifferentiated cells (≅1 log), no
significant differences were found between cell lines or
viral strains (Fig. 3-III). Cell viability was evaluated using a
XTT/PMS vital dye assay. As shown in Fig. 3-IV 20% of hESC or
hESC-EB remained viable 24 or 48 h after CVB3 1/10
infection, respectively. As expected, an increase in cell
viability was observed when 10-fold serial dilutions of CVB3
were used. Viral replication was further confirmed by
detection of the viral RNA by RT-PCR and immunostaining
of viral protein 1 (VP1) in hESC (Fig. 4-I left panel and II) and
EB (Fig. 4-I right panel and III). Thus, we have shown that
both undifferentiated hESC and hESC-derived contractile EB
are susceptible to a productive CVB infection.Human IFN-Iβ inhibited CVB replication
To determine whether IFN-Iβ treatment inhibited CVB
replication, hESC and hESC-EB cultures were treated with
100 U of recombinant human IFN-Iβ 24 h prior to viral
infection. No changes in cell morphology or viability wereFigure 3 Coxsackievirus B variants replicated and induced cyto
representative images of (I) hESC (HUES-5, WA09 and HUES-16) colon
The scale bars represent 200 μm. Abbreviations: CVB1, Coxsackievir
serotype 3. (III) Infectivity titration of infected cell supernatant perf
unit (PFU) assay at 24 (hESC) or 48 h pi (hESC-EB). Each bar repres
results were observed after infection with CVB2, CVB4 or CVB5. (IV) C
24 h pi of hESC or 48 h pi of contractile EB using 10-1 to 10-3 seria
independent experiments (*Pb0.05).observed in cell culture media containing IFN-Iβ 100 U or
less. However, with 500 U some alteration in cell morphology
was observed, (data not shown). These results indicated
untreated hESC exhibited cpe changes throughout the
monolayer or the beating area of EB, while IFN-Iβ treated
cells were protected from viral-induced lysis (Fig. 5-I and II,
respectively). Moreover, these findings correlated with a
decline in viral titers (N1 log) in culture supernatants at 24
(hESC) or 48 h (hESC-EB), and with a dose-dependent an
increase in cell viability (Fig. 5-III and IV, respectively).
Importantly, when the hESC-EB were treated with IFN-Iβ
they retained their contractile activity for 48 h pi, whereas
the untreated EB stopped beating (supplementary data).Discussion
Although murine embryonic stem cells have been cultured for
almost twenty years, culture conditions for hESC remained
elusive, and it took researchers a much longer time to define
these complex conditions. Human embryonic stem cells were
discovered a decade ago, after Thomson and co-workers
developed a culture system able to maintain hESC indefinitely
in an undifferentiated state (Thomson et al., 1998). In recent
years, multiple protocols have been developed to produce
various adult cells in vitro. Kehat et al. were the first to
demonstrate that hESC can differentiate into cardiomyocytes
(Kehat et al., 2001). Multiple publications thereafter proved
these cells were mature cardiomyocytes, as defined by their
gene and protein expression, as well as their physiological
properties (He et al., 2003; Xu et al., 2002). Even though hESC-
derived cardiomyocytes probably retain features related to
their fetal origin; they are neverthelessmature enough to beat
spontaneously and to respond to cell surface signals, such as
incubation with NE which rapidly increases their beating rate.
Relatively few studies have evaluated CAR expression in
hESC, although a recent paper reported striking variation in
adenovirus infection rates among different hESC lines,
correlating with CAR expression (Brokhman et al., 2009),
the three cell lines studied in this paper, WAO9, HUES-5 and
HUES-16, expressed CAR at similar levels. This difference
may perhaps have due to differences in cell lines or culture
conditions used. However, CAR transcript was always more
abundant in hESC than in hESC-EB, a finding in agreement
with expression levels found in embryos and adult heart
tissue (Freimuth et al., 2008). Interestingly, CAR has been
reported to be highly expressed in the hearts of DCM
patients, and it has been suggested that these patients
may be more susceptible to heart CVB infection (Noutsias et
al., 2001). As for DAF, a protein present on the surface of
normal cardiomyocytes (Zimmermann et al., 1990), cognatepathic changes in both hESC and hESC-EB. The figure shows
ies 24 h pi, and (II) hESC-EB at day 14 of differentiation, 48 h pi.
us subgroup B, serotype 1 and CVB3, Coxsackievirus subgroup B,
ormed with 100 μl of 10-fold serial dilutions in a plaque forming
ents the mean±SEM of three independent experiments. Similar
ell viability was measured by using the XTT/PMS vital dye assay at
l dilutions of CVB3. Each bar represents the mean±SEM of two
17Coxsakievirus B infection and respond to interferon Iβ treatmentmRNA was also expressed at similar levels in all three cell
lines studied. But, in contrast to CAR, mRNA levels were
higher in EB than in undifferentiated cells.Both CAR and DAF have been implicated in CVB infection.
Molecular events underlyingCVBentry havebeendescribed for
polarized (Coyne and Bergelson, 2006) and nonpolarized cells
18 M.E. Scassa et al.(Patel et al., 2009). However, the exactmechanism involved in
CVB infection of cardiomyocytes is unknown. Moreover, some
aspects of infection could be specific to human cells. For
example, CVB can interacts with human and murine CAR.
However, unlike human DAF, CVB does not bind to rodent DAF
protein analogues (Spiller et al., 2000) precluding use of a
suitable rodentmodel. Additionally, design of a human in vitro
model systemhas been hindered by difficulties associatedwith
culturing human cardiomyocytes derived from adult heart
tissues as well as by low availability of cardiac cell cultures
from fetal sources (Kandolf et al., 1985). The emergence of
embryonic stem cells and protocols for cardiomyocyte
differentiation has allowed modern research to overcome
these problems. After testing our cell lines for the presence of
viral receptors, we subsequently assessed the susceptibility of
these cell lines to CVB infection. Pioneer work by Feuer et al.
performed in mice revealed CVB3 preferentially targets
proliferating neural stem cells located in the neonatal central
nervous system (Feuer et al., 2003, 2005). In our study, we
extended these observations showing both hESCs and hESC-EB
presented susceptibility to CVB infection. Several lines of
evidence suggest host cell status may play a key role in
determining CVB infection outcome. In this regard, prolifer-
ation appears to favour productive CVB infection (Tabor-
Godwin et al., 2010), and perhaps also contribute to
CVB enhanced replication observed in hESC compared to
hESC-EB.
The data presented herein agree with previous studies
performed with cardiomyocytes derived from human fetal
tissue (Kandolf et al., 1985) or newborn mice (Gomez et al.,
1993). We also show that IFN-Iβ administration prior to
infection was able to reduce viral replication and subsequent
cell death. This cytokine was chosen because previous
published reports have shown IFN-Iβ treatment eliminates
cardiotropic viruses, improving left ventricular function in
patients with myocardial persistence of viral genomes and
left ventricular dysfunction (Kuhl et al., 2003). Although
clinical trials with IFN are still in progress, the results seem
promising (Matsumori, 2007). The model described here is
novel, relatively simple and can be easily reproduced in anyFigure 4 Intracellular presence of viral RNA and VP1 protein.
(I) RT-PCR of total RNA obtained from hESC and contractile areas
of EB performed at 8 or 48 h pi, respectively in order to
determine the presence of CVB1 or CVB3 RNA. Mock (uninfected
control cells). β-actin was used as positive control. (II) The
figure shows representative images of undifferentiated HUES-5
colonies 8 h pi with CVB1 and CVB3 stained for VP1. The nuclei
were counterstained with DAPI. The scale bars represent
200 μm. (III) hESC-EB at day 14 of differentiation and 48 h pi
were stained for VP1 and Nkx2.5 (middle and bottom panels). A
representative contractile EB was stained for cTnT and
simultaneously used for rabbit IgG isotype control (ic)(top
panel). The scale bars represent 100 μm. A merged image of a
representative contractile area stained with VP1 and Nkx2.5
(bottom panel) is shown. The scale bars represent 50 μm.
Abbreviations: VP1, Viral Protein 1; CVB1, Coxsackievirus
subgroup B, serotype 1; CVB3, Coxsackievirus subgroup B,
serotype 3. Similar results were observed when undifferentiated
or differentiated cells were infected with CVB2, CVB4 or CVB5.laboratory currently working on hESC. Our findings suggest
this model can be useful for the evaluation of potential drug
therapies for viral myocarditis.
19Coxsakievirus B infection and respond to interferon Iβ treatmentConclusions
In conclusion, we used hESC and hESC-EB to analyze the
presence of specific cell markers, such as CVB and IFN-I
receptors. Additionally cell susceptibility to CVB infection was
analyzed by titrating supernatant infectivity, detecting
eventual associated cpe and intracellular presence of viral
RNA and protein. Finally, CVB infection was ameliorated by
IFN-Iβ treatment. We propose this model as a valid tool for
additional studies investigating potential mechanisms under-
lying CVB infection in cardiomyocytes or for use in drug testing.
Materials and Methods
Reagents
Fluorescein isothiocyanate (FITC)-conjugated anti-mouse
IgG, FITC-conjugated anti-rabbit IgG, Texas Red-X (TR)-
conjugated anti-rabbit IgG, TR-conjugated anti-mouse IgG
and 4,6-diamidino-2-fenilindol (DAPI) were purchased from
Molecular Probes/Invitrogen (Carlsbad, CA). Murine mono-
clonal antibodies (mAb) anti-SSEA4 (clone 813-70), anti-Tra-
1-60 (TRA-1-60), anti-Oct-3/4 (clone C-10), anti-GATA-4
(clone G-4) and anti-cardiac Troponin T (clone CT3) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The mAb anti-DAF (clone IA10) was purchased from Pharmin-
gen (San Diego, CA). The rabbit polyclonal anti-Nanog (clone
H-155), anti-ANP (clone FL-153), anti-Nkx2.5 (clone H-114)
and anti-CAR were purchased from Santa Cruz Biotechnolo-
gy. Recombinant human IFN-Iß was obtained from InvivoGen
(San Diego, CA). Random hexamers, SuperScript III reverse
transcriptase, Trizol, DMEM and knock-out serum replace-
ment (KSR) were from Invitrogen. MatrigelTM was from BD
Bioscience (San Jose, CA). The basic fibroblast growth factor
(bFGF) was purchase from R&D Systems (Minneapolis, MN).Figure 5 IFN-Iβ treatment reduced virus replication and cell
death of infected cultured hESC and hESC-EB. (I) Representative
images of HUES-5 hESC incubated with 100 units of IFN-Iβ 24 h
prior to and during virus infection. The figure shows colonies
control cells (A-B), control cells treated with IFN -Iβ (C-D),
infected with CVB1 (E-F), treated with INF-Iβ and infected with
CVB1 (G-H), infected with CVB3 (I-J) and treated with IFN-Iβ and
infected with CVB3 (K-L). The scale bars represent 200 μm.
(II) Representative images of HUES-5 hESC-EB incubated with
100 units of IFN-Iβ 24 h prior to and during virus infection. The
figure shows colonies control EB (A-B), control EB treated with
IFN -Iβ (C-D), infected with CVB3 (E-F), and treated with IFN-Iβ
and infected with CVB3 (G-H). Arrow shows CVB3-related cpe in
contractile areas. (III) Infectivity titration of infected cell
supernatants performed with 100 μl of 10-fold serial dilutions
in a plaque forming unit (PFU) assay at 24 h pi (hESC) or 48 h pi
(hESC-EB) with or without IFN-Iβ treatment. (IV) Cell viability
was measured by using the XTT/PMS vital dye assay at 24 h pi of
hESC or 48 h pi of hESC-EB untreated or treated with 25 to 100 U
of IFN-Iβ 24 h prior to and during virus infection. Each bar
represents the mean±SEM of two independent experiments
(*Pb0.05). Abbreviations: IFN-Iβ, Type I Interferon β; CVB1,
Coxsackievirus subgroup B, serotype 1; CVB3, Coxsackievirus
subgroup B, serotype 3.All of the other reagents were obtained from Sigma Chemical
Co. (St. Louis, MO).Cell lines and culture
The human embryonic stem cell (hESC) line WAO9 was
purchased from WiCell Research Institute (WI), and the hESC
20 M.E. Scassa et al.lines HUES-5 and HUES-16 were acquired from Harvard
University and the Howard Hughes Medical Institute (MA) at
low passages (p15 to p20). The hESC lines were maintained on
an inactivated mouse embryonic fibroblast (MEF) feeder layer
in medium comprised of Dulbecco's Modified Eagle's Medium/
Ham's F12 (DMEM/F12) supplemented with KSR 20% 2 mM non-
essential amino acids, 2 mM L-glutamine, 100 U/ml penicillin,
50 μg/ml streptomycin, 0.1 mM β-mercaptoethanol and 4 ng/
ml of bFGF on diluted (1/40) MatrigelTM coated dishes in MEF-
conditioned medium. For the conditioning medium, 3×106
inactivated MEF cells were incubated for 24 h with 25 ml of
DMEM/F12 medium supplemented with 5% KSR and 2 ng/ml of
bFGF (in addition to the other aforementioned supplements)
and stored at -20 °C. After thawing, fresh aliquots of KSR and
bFGF were added to the medium to render a final concentra-
tion of 20% and 4 ng/ml, respectively.
To induce differentiation, hESC colonies were dispersed
with 1 mg/ml of collagenase IV (Invitrogen) for 5 min. The cells
were then transferred to non-adherent Petri dishes containing
DMEM supplemented with 20% (vol/vol) fetal bovine serum
(FBS, Gibco), 2 mM L-glutamine, 100 U/ml penicillin and
50 μg/ml streptomycin used as differentiation medium. The
cells were incubated in suspension at 37 °C with 5% CO2 for
7 days. During the incubation the cells aggregated to form EB,
which were then plated on to 0.1% gelatin coated 24-well
microplates and cultured for an additional 7 days. Normally,
within the first 2-4 days after plating, contracting areas were
observed in the outgrowth of the EB.
The HeLa cells that were used for transfections, virus
propagation and viral titrations were obtained from ABAC
(Asociación Banco Argentino de Células, Argentina) and were
maintained as monolayers in MEM supplemented with 10%
(vol/vol) FBS, 2 mM L-glutamine, 25.5 mM sodium bicarbon-
ate and 50 μg of gentamicin/ml.
Virus
A CVB1 derived from an infectious cDNA clone has been
previously described (Iizuka et al., 1991), as well as a
myocarditic strain of CVB3 (Gomez et al., 1991, 1993). CVB2,
CVB4 andCVB5were obtained from theAmericanTissue Culture
Collection (ATCC). The viral stocks were prepared by partially
purifying the virus through a 30% sucrose cushion, as previously
described (Rinehart et al., 1997).
Cell infection
The cells were infected at undifferentiated (day 0, hESC) or
differentiated (day 14, hESC-EB) stages with a multiplicity of
infection (MOI) of 1 for 1 h at 37 °C. Mock infection was
performed by replacing the same volume of virus inoculum
with HeLa cell supernatant from uninfected cells. The cells
were then washed and maintained in conditioned medium or
differentiation medium as needed.
Infectivity titration
The infectivity titration was performed with 100 μl of 10-fold
serial dilutions of infected cell supernatants as previously
described (Gomez et al., 1991).Immunostaining and fluorescence microscopy
The hESC or hESC-EB were analyzed for in situ immunoflu-
orescence. Briefly, the cells were rinsed with ice-cold PBS
and fixed in PBSA (PBS with 0.1% bovine serum albumin)
with 4% formaldehyde for 45 min. After two washes cells
were permeabilized with 0.1% Triton X-100 in PBSA with
10% normal goat serum for 30 min, washed twice and
stained with the corresponding primary antibodies. Fluo-
rescent secondary antibodies were used to localize the
antigen/primary antibody complexes. The cells were
counterstained with DAPI and examined under a Nikon
Eclipse TE2000-S inverted microscope equipped with a 20X
E-Plan objective and a super high-pressure mercury lamp.
The images were acquired with a Nikon DXN1200F digital
camera, which was controlled by the EclipseNet software
(version 1.20.0 build 61).RNA isolation and RT-PCR
Total RNA was isolated from hESC or from contractile
areas of hESC-EB by mechanical scraping with a scalpel
under microscope and Trizol, as recommended by the
manufacturer. DNase treatment was performed with an
RNase-free DNase Kit (Qiagen). cDNA was synthesized from
500 ng of total RNA with 15 mM of random hexamers and
SuperScript III reverse transcriptase, according to manu-
facturer's instructions. The cDNA samples were diluted 10-
fold, and the PCR reaction was conducted at an annealing
temperature of 55 °C. All of the reactions were within the
linear range of amplification. For the real-time PCR
studies, PCR amplification and analysis were performed
with a Line-Gene instrument (Bioer). The TAQurate green
real-time PCR MasterMix (Epicentre Biotechnologies) was
used for all reactions, following manufacturer instruc-
tions. A melting curve analysis was performed immediately
after amplification at a linear temperature transition rate
of 0.3 °C/s from 70 °C to 89 °C with continuous fluores-
cence acquisition. After real-time PCR, the amplicon size
was confirmed by gel electrophoresis. The primers
sequences and sizes of the amplified fragments are
shown in Table 1.Cell viability assay
hESC were plated onto matrigel coated 96-well tissue culture
plates at densities between 1×104 – 3×104 cells per well and
grown until confluence. After 7 days of suspension culture,
individual EBs were plated onto 0.1% gelatin coated 96-well
microplates and cultured for an additional 7 days as
previously described. 24 h pi (hESC) or 48 h pi (contractile
EB), 50 μg/well of activated 2,3-bis (2-methoxy-4-nitro-5-
sulfophenyl)-5 [(phenylamino)carbonyl]-2 H-tetrazolium hy-
droxide (XTT) in PBS containing 0.3 μg/well of the interme-
diate electron carrier, N-methyl dibenzopyrazine methyl
sulfate (PMS) were added (final volume 100 μl) and incubat-
ed for 1-2 h. Cellular metabolic activity was determined by
measuring the absorbance of the samples with a spectro-
photometer (ELISA reader) at a wavelength of 450 nm and
subtracting the background absorbance at 690 nm.
Table 1 Primers used for the PCR experiments and size of amplified fragments
Gene Fragment size Primers sequence (5´-3´)
Forward Reverse
Oct -4 126 CTGGGTTGATCCTCGGACCT CACAGAACTCATACGGCGGG
Nanog 109 AAAGAATCTTCACCTATGCC GAAGGAAGAGGAGAGACAGT
GATA-4 218 CATCAAGACGGAGCCTGGCC TGACTGTCGGCCAAGACCAG
GATA-6 213 CCATGACTCCAACTTCCACC ACGGAGGACGTGACTTCGGC
c-myc 109 ATGAAAAGGCCCCCAAGGTAG CGTTTCCGCAACAAGTCCTCT
cTnT 107 ATGATGCATTTTGGGGGTTA CAGCACCTTCCTCCTCTCAG
MESP1 111 TGAGGAGCCCAAGTGACAA CTCTTCCAGGAAAGGCAGTCT
α-MHC 413 GTCATTGCTGAAACCGAGAATG GCAAAGTACTGGATGACACGCT
Isl-1 201 CACAAGCGTCTCGGGATTGTGTTT AGTGGCAAGTCTTCCGACAA
ß-actin 125 CAATGTGGCCGAGGACTTTG CATTCTCCTTAGAGAGAAGTGG
CAR 293 AGTCCCGAAGACCAGGGACC ACCTGAAGGCTTAACAAGAA
DAF 82 AATGGTCCACAGCAGTCGAAT GGTACATCAATCTGACCATTTCGTA
IFNAR1 326 GTGATACACATCTCTCCTGG GTATAATCCCATTTAAGAACATG
IFNAR2 394 GAGTAAACCAGAAGATTTGAAG CGTGTTTGGAATTAACTTGTC
GAPDH 98 ACAGCCTCAAGATCATCAG GAGTCCTTCCACGATACC
Entero 115 CGGCCCCTGAATGCGGCTAA GAAACACGGACACCCAAAGTA
21Coxsakievirus B infection and respond to interferon Iβ treatmentStatistical analysis
All of the results are expressed as the mean±SEM. The
student's paired t test was used to determine significant
differences between means, and P values below 0.05 were
considered to be statistically significant.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2010.09.002.
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